… cytokines, IL-6 is a key mediator for the development of cytokine storm in COVID-19 cases. …
, indicating that they can potentially be used for treating patients with COVID-19. Nevertheless…

… about the management of cytokine storm in COVID-19. From … can be beneficial in managing
cytokine storm. The use of … regarding their use for cytokine storm in COVID-19 is limited. …

… IL-6 blockade with monoclonal antibodies to either IL-6 or the IL-6 receptor. There have
been many reported clinical trials exploring inhibition of IL-6 for the treatment of COVID-19; no …

… It is tempting to conclude that patients with “COVID-CS” should be treated for cytokine
storm. However, randomised controlled trials (RCTs) of interleukin (IL)-6 blockade for severe …

… It is anticipated that this work will provide insights on the development of novel therapeutics
toward efficacious management of COVID-19 cytokine storm and other inflammatory …

… Of note some clinical data suggest that treatment with the CCR5 blocking antibody (ie …
strategy for COVID 19 treatment [56]. More specifically, Patterson et al., reported that treatment with …

… treatment of COVID-19, downregulation of the cytokine storm … to suppress the cytokine storm
associated with inflammation … the cytokine storm syndrome observed in COVID-19 patients …

… treatment of critically unwell patients with COVID-19. This review demonstrates that, at least
until the time of writing this paper, there is no proven cytokine blocking agents for COVID-19, …

… Our results provide a justification for a treatment strategy with an early onset of proactive
anti-inflammatory therapy and anti-COVID-19 convalescent plasma in patients at a high risk for …

… candidates for the cytokine release syndrome (CRS) treatment in COVID-19 infection.
This review was conducted to discuss all the possible signalling pathways involved in …